about
Unsung Hero Robert C. GalloPost-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatmentEpstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infectionTelomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children.Viral load detection using dried blood spots in a cohort of HIV-1-infected children in Uganda: correlations with clinical and immunological criteria for treatment failureToll-like receptor 9 polymorphisms influence mother-to-child transmission of human immunodeficiency virus type 1.The role of genetic variants of Stromal cell-Derived Factor 1 in pediatric HIV-1 infection and disease progression.Relationship between non-Hodgkin's lymphoma and blood levels of Epstein-Barr virus in children in north-western Tanzania: a case control study.The immunological and virological consequences of planned treatment interruptions in children with HIV infection.Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virusAntiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.Nucleoside and nucleotide reverse transcriptase inhibitors in children.Premature aging and immune senescence in HIV-infected children.Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes.Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy.Current and future antiretroviral treatment options in paediatric HIV infection.Virus-host interactions in paediatric HIV-1 infection.Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.Epstein-Barr virus and telomerase: from cell immortalization to therapy.Italian consensus statement on paediatric HIV infection.Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications.Pediatric human immunodeficiency virus infection and cancer in the highly active antiretroviral treatment (HAART) era.Telomeres, telomerase and colorectal cancer.Epstein-Barr virus load in children infected with human immunodeficiency virus type 1 in Uganda.Dried blood spot sampling for detection of monoclonal immunoglobulin gene rearrangement.hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.In young men sperm telomere length is related to sperm number and parental age.hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1.Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells.Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells.Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts.Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.Analysis of Epstein-Barr virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumours.A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies.Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.Antiretroviral activity of furocoumarins plus UVA light detected by a replication-defective retrovirus.Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.
P50
Q22065525-E98DDE46-D7CF-4487-83FA-9B4EDB744EFEQ26798038-84D7275B-6580-4B21-B634-EF4663A88249Q27022706-8D467D97-A51B-446E-B7B4-15EBFE257E17Q30248577-19FD7CEB-D10A-4E85-9FA2-A1655865F6BCQ33372329-CFD1AFF7-B913-4A57-B0B7-A6510B8B4A9AQ33900125-611603A0-9980-47F8-A93C-EB1A6FA7D349Q33920072-9D1535BA-93DA-48E4-9B82-AA5861860BF3Q34409877-7C5E03B2-4811-4E6C-A652-53B0F5090B11Q34538061-234E688A-83C1-4299-B4CD-E21234A11636Q35032305-0B948785-6516-42CE-BFA6-BB5AFD910E43Q35643026-01B745AA-1AD6-4832-B805-E06B19D9EDFAQ36346985-5E52D228-D6B3-4F2B-8990-AA92354CABCEQ36681036-5A53DECF-BC38-4774-B10E-9C9157D6FB8DQ36885640-4FFDAEAA-7758-4C62-B370-4E9A03FE5424Q36903898-2E346CFE-25B8-4526-9784-99CF99D7192BQ36933913-40672E35-8EF2-4225-BB90-2DA3A96F84F6Q37132742-6EBFA462-6E53-47AB-A4DC-B1FE08F2943EQ37163343-48F5C059-49A9-4FAB-B2BF-A0ADF086F2BBQ37447380-2F504F4A-EEB1-4BDC-BA42-6E7F7C5D697FQ37603448-775FB78F-929D-4EAB-B4A4-028BADEAE648Q37619108-C5704470-EF16-491D-8C1B-B749623719EDQ37761853-6552F6E4-946D-4AD4-8BAF-8D39D5A1A6F0Q37765230-75AF2ED7-0440-41C8-848A-1A96CDB5DE4EQ38186881-07A3531D-FBDB-4398-B03E-429C76160FA7Q38195033-7D131502-52D6-4AB3-8350-A3BB25FF9EB1Q38863161-26414347-5933-43CF-8A1F-3D1A9A6056D4Q39107171-5440E6F3-4722-46EC-B5C0-C34BC7938882Q39187962-9AE1F095-8822-4332-BED2-9B69CFF33D9CQ39324959-8BF2DC33-0EB1-4DA1-9996-ABC8A0DB9B42Q40148116-55309C75-1DD0-48A8-AB2D-4401923C0C01Q40551750-CB28C377-251D-4F43-951B-0693C3BF3E87Q40565403-FB3B2480-8751-4FE0-A397-068975C639E8Q40670895-98E684C3-6B36-4F31-AF1F-12404CA948DCQ40893503-1FD8C859-AD3F-4B50-BA2E-59F323D8E567Q41102458-674B3ED0-52C0-4518-B958-D8F77654F215Q41146620-BAD1531B-E834-4C4D-9056-D8C3A455EF73Q41299147-FEF88F03-1958-4EA8-8CED-2B75793F8E35Q41372477-AA2BEF02-6A35-44AC-A2B6-CE0F1EC15872Q41420718-6260D482-9F8B-4A14-BF0A-AC232EC55285Q41588189-0A0E85E4-7F23-4CA0-B617-28E683D4EF4D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anita De Rossi
@ast
Anita De Rossi
@en
Anita De Rossi
@es
Anita De Rossi
@nl
type
label
Anita De Rossi
@ast
Anita De Rossi
@en
Anita De Rossi
@es
Anita De Rossi
@nl
prefLabel
Anita De Rossi
@ast
Anita De Rossi
@en
Anita De Rossi
@es
Anita De Rossi
@nl
P1053
L-3128-2015
P106
P1153
7102867046
P21
P31
P3829
P496
0000-0001-6435-7509